A recent study has identified a promising new strain of Ligilactobacillus salivarius, designated CNCM I-4866, with potential as a probiotic for addressing intestinal inflammation. Through a series of in vivo and in vitro experiments, researchers observed significant reductions in colonic damage and inflammation markers following treatment with this strain. Moreover, transcriptomic analysis revealed its ability to down-regulate pro-inflammatory cytokines, while in vitro assays demonstrated its capacity to enhance intestinal integrity and inhibit pathogens. Importantly, the strain exhibited high resistance to bile salts and lacked antibiotic gene resistance, further supporting its safety and potential as a therapeutic option. These findings suggest that L. salivarius CNCM I-4866 holds promise as a probiotic candidate for managing intestinal inflammation, offering a steady anti-inflammatory profile.
Source: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1270974/full
